SCHEMBL20004241

SCHEMBL20004241

CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C)ccc3c1C2=O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 20/20 0.83
KDR P35968 5/20 0.83
EML4 Q9HC35 2/20 0.83
GAK O14976 1/20 0.83
ACOX3 O15254 1/20 0.83
NR1I2 O75469 1/20 0.83
ABCB11 O95342 1/20 0.83
EGFR P00533 1/20 0.83
ESR1 P03372 1/20 0.83
PGR P06401 1/20 0.83
RET P07949 1/20 0.83
ROS1 P08922 1/20 0.83
ADORA3 P0DMS8 1/20 0.83
PHKG2 P15735 1/20 0.83
FER P16591 1/20 0.83
EPHA1 P21709 1/20 0.83
DRD1 P21728 1/20 0.83
SLC6A2 P23975 1/20 0.83
PDE4A P27815 1/20 0.83
SLC6A4 P31645 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22056011 0.92 ALK (0.80) ALKKDREML4GAKACOX3
SCHEMBL898196 0.91 ALK (0.79) ALKKDREML4GAKACOX3
SCHEMBL1756022 0.91 ALK (0.79) ALKKDREML4GAKACOX3
SCHEMBL29940275 0.91 ALK (0.79) ALKKDREML4GAKACOX3
Alectinib SCHEMBL896753 0.91 ALK (1.00) ALKKDREML4GAKACOX3
SCHEMBL29940598 0.91 ALK (0.86) ALKKDREML4GAKACOX3
Alectinib SCHEMBL29352499 0.91 ALK (1.00) ALKKDREML4GAKACOX3
SCHEMBL26972926 0.91 ALK (0.86) ALKKDREML4GAKACOX3
Alectinib SCHEMBL18631602 0.91 ALK (1.00) ALKKDREML4GAKACOX3
SCHEMBL30622252 0.90 ALK (0.77) ALKKDREML4GAKACOX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858897-B2 Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-02 US disclosed
WO-2020249048-A1 ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF 上海科技大学 2020-12-17 WO disclosed
EP-3613729-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-02-26 EP disclosed
EP-3345903-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2019-10-09 EP disclosed
EP-3345903-A1 TETRACYCLIC COMPOUNDS Chugai Seiyaku Kabushiki Kaisha (JP) 2018-07-11 EP disclosed
EP-2975024-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2018-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858897-B2 Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK SRPK3, SRPK1, SRPK2 ALK 4/4885KDR 1280/4885EML4 4596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.